Humana Inc (HUM) Position Trimmed by Smith Graham & Co. Investment Advisors LP

Share on StockTwits

Smith Graham & Co. Investment Advisors LP decreased its position in shares of Humana Inc (NYSE:HUM) by 3.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,726 shares of the insurance provider’s stock after selling 910 shares during the quarter. Smith Graham & Co. Investment Advisors LP’s holdings in Humana were worth $8,032,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Sun Life Financial INC raised its stake in Humana by 120.7% during the second quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock worth $111,000 after acquiring an additional 204 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in Humana by 2,984.6% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock worth $119,000 after acquiring an additional 388 shares in the last quarter. Palo Capital Inc. acquired a new position in Humana during the third quarter worth about $178,000. Wall Street Access Asset Management LLC acquired a new position in Humana during the third quarter worth about $209,000. Finally, Baxter Bros Inc. acquired a new position in Humana during the third quarter worth about $211,000. 92.57% of the stock is owned by institutional investors and hedge funds.

HUM has been the subject of several recent research reports. Piper Jaffray Companies upped their price objective on Humana from $355.00 to $380.00 and gave the company an “overweight” rating in a research note on Friday, August 24th. Bank of America upped their price objective on Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, August 2nd. Royal Bank of Canada reaffirmed a “hold” rating and issued a $318.00 price objective on shares of Humana in a research note on Thursday, August 2nd. SunTrust Banks upped their price objective on Humana to $380.00 and gave the company a “hold” rating in a research note on Wednesday, September 19th. Finally, Zacks Investment Research downgraded Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Humana presently has an average rating of “Buy” and an average price target of $339.79.

In other Humana news, insider Roy A. Beveridge sold 14,306 shares of the stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $324.25, for a total transaction of $4,638,720.50. Following the transaction, the insider now directly owns 15,274 shares in the company, valued at approximately $4,952,594.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bruce D. Broussard sold 18,000 shares of the stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $328.66, for a total value of $5,915,880.00. Following the transaction, the chief executive officer now owns 71,085 shares in the company, valued at $23,362,796.10. The disclosure for this sale can be found here. Insiders have sold a total of 40,284 shares of company stock worth $13,147,715 over the last 90 days. Company insiders own 0.60% of the company’s stock.

Shares of HUM stock opened at $317.61 on Tuesday. Humana Inc has a one year low of $231.90 and a one year high of $341.30. The company has a market capitalization of $43.84 billion, a P/E ratio of 27.12, a P/E/G ratio of 1.59 and a beta of 0.97. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.79 by $0.17. Humana had a return on equity of 17.43% and a net margin of 2.48%. The business had revenue of $14.26 billion for the quarter, compared to analysts’ expectations of $14.16 billion. During the same period in the prior year, the business posted $3.49 earnings per share. As a group, sell-side analysts anticipate that Humana Inc will post 14.18 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, October 26th. Shareholders of record on Friday, September 28th were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date of this dividend was Thursday, September 27th. Humana’s payout ratio is 17.08%.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Further Reading: Are Wall Street analysts’ stock ratings worth following?

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply